ANAB — ANAPTYSBIO, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1370053 ·
Last close
$46.21
Market Cap
$1.37B
52W High
$72.36
52W Low
$20.18
ADV30
574,558
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 25,556,000 | — | -34,637,000 | -52,884,000 | 329,684,000 | 248,469,000 | 316,937,000 |
| Dec 2025 | 108,249,000 | — | 66,901,000 | 49,614,000 | 364,395,000 | 238,196,000 | 327,185,000 |
| Sep 2025 | 76,320,000 | — | 34,704,000 | 15,113,000 | 353,098,000 | 109,833,000 | 382,514,000 |
| Jun 2025 | 22,263,000 | — | -26,170,000 | -38,630,000 | 335,250,000 | 44,298,000 | 379,983,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,478,000
Investing CF
$248,168,000
Financing CF
$-102,814,000
CapEx
$-69,000
Dividends Paid
—
Buybacks
$-64,202,000
EPS Diluted TTM
$-1.08
As of
2026-09-06
Balance + Analyst (yfinance extras)
Retained Earnings
$-825,443,000
Inventory
—
Receivables
$25,747,000
ST Investments
$37,986,000
EBIT TTM
$56,064,000
Pretax Income TTM
$-26,627,000
Interest Exp TTM
$82,691,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$232,388,000
EBITDA
$41,341,000
Free Cash Flow
$8,323,875
Enterprise Value
$1,558,565,632
Total Cash
$286,455,008
Total Debt
$277,355,008
Shares Out
29,608,481
Trailing EPS
$-1.02
Book Value
$0.44
ROE
-114.6%
ROA
6.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 234,603,000 | 226,902,000 | -13,232,000 | 364,395,000 | 327,185,000 | 37,210,000 | 19,697,000 |
| Dec 2024 | 91,280,000 | 66,152,000 | -145,231,000 | 483,834,000 | 412,966,000 | 70,868,000 | -135,337,000 |
| Dec 2023 | 17,157,000 | -157,072,000 | -163,619,000 | 452,389,000 | 364,286,000 | 88,103,000 | -120,800,000 |
| Dec 2022 | 10,287,000 | -115,154,000 | -128,724,000 | 610,383,000 | 348,280,000 | 262,103,000 | -73,593,000 |
TTM Snapshot
Revenues TTM
$232,388,000
NetIncome TTM
$-26,787,000
OpCashFlow TTM
—
Assets (Latest)
$329,684,000
Forward EPS
$5.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.36B | $14.55 | — |
| OMER | OMEROS CORP | $1.38B | $19.12 | — |
| NKTR | NEKTAR THERAPEUTICS | $1.39B | $40.80 | — |
| GHRS | GH Research PLC | $1.40B | $20.45 | — |
| KARD | Kardigan, Inc. | $1.33B | $14.20 | — |
News headlines (Yahoo Finance, 1h cache)
AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story
2026-10-09 04:29 · Yahoo
AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise
2026-10-08 23:17 · Yahoo
AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?
2026-09-26 03:38 · Yahoo
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
2026-09-21 21:35 · Yahoo
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
2026-09-21 20:15 · Yahoo
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)
2026-09-14 18:34 · Yahoo
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-01 20:15 · Yahoo
GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control
2026-08-17 15:03 · Yahoo
What Makes AnaptysBio (ANAB) an Investment Bet?
2026-07-14 14:56 · Yahoo
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
2026-05-21 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.